TD Cowen analyst Ritu Baral maintains $Neurogene (NGNE.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 45.4% and a total average return of 11.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Neurogene (NGNE.US)$'s main analysts recently are as follows:
The stock of Neurogene is currently trading 'near cash' following disclosures about a Serious Adverse Event in its NGN-401 high dose trial and the termination of its Battens program. Despite these setbacks, management anticipates no clinical hold after their discussions with the FDA, noting the safety of lower doses.
The firm updated its projections for 3Q24 earnings and adjusted its expectations after learning that a trial participant of NGN-401 was in critical condition following administration of the high dose. Furthermore, the anticipated market share of NGN-401 in the Rett syndrome gene therapy market has been adjusted to 50%.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
TD Cowen分析師Ritu Baral維持$Neurogene (NGNE.US)$買入評級。
根據TipRanks數據顯示，該分析師近一年總勝率為45.4%，總平均回報率為11.1%。
此外，綜合報道，$Neurogene (NGNE.US)$近期主要分析師觀點如下：
在披露其 NGN-401 高劑量試驗中的嚴重不良事件以及其 Battens 計劃終止之後，Neurogene的股票目前以 「接近現金」 的交易。儘管遇到了這些挫折，但管理層在與美國食品藥品管理局討論後預計不會暫停臨床治療，同時指出較低劑量的安全性。
在得知 NGN-401 的一名試驗參與者在服用高劑量後情況危急後，該公司更新了對 24 年第三季度收益的預測並調整了預期。此外，NGN-401 在雷特綜合徵基因療法市場的預期市場份額已調整至50％。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
